Isolation of scFv antibody fragments against HER2 and CEA tumor antigens from combinatorial antibody libraries derived from cancer patients

Biologicals

Volumn 41, Issue 6, 2013, Pages 345-354

  Ayat, Hoda ^a,b,e   Burrone, Oscar R ^c   Sadghizadeh, Majid ^b   Jahanzad, Eissa ^d   Rastgou, Nasrin ^e   Moghadasi, Sarrira ^e   Arbabi, Mehdi ^f,g,h  

^a SHAHREKORD UNIVERSITY   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^f NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^g CARLETON UNIVERSITY   (Canada)

^h UNIVERSITY OF GUELPH   (Canada)

Author keywords

Antibody library; CEA; HER 2 neu; Phage display

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INTERNALIZATION; PHAGE DISPLAY; PRIORITY JOURNAL;

ANTIBODY LIBRARY; CARCINOEMBRYONIC ANTIGEN; CEA; CONTROL; CTRL; ECD; EXTRACELLULAR DOMAIN; HER-2/NEU; MAB; MONOCLONAL ANTIBODY; PHAGE DISPLAY; SCFV; SINGLE CHAIN FRAGMENTS;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE LIBRARY; RECEPTOR, ERBB-2; SEQUENCE HOMOLOGY, AMINO ACID; SINGLE-CHAIN ANTIBODIES;

EID: 84888013358     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2013.05.004     Document Type: Article

References (68)

1. Souriau C., Hudson P.J. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 2003, 3(2):305-318.
2. Funaro A., Horenstein A.L., Santoro P., Cinti C., Gregorini A., Malavasi F. Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 2000, 18(5):385-401.
3. Mayer A., Chester K.A., Flynn A.A., Begent R.H. Taking engineered anti-CEA antibodies to the clinic. JImmunological Methods 1999, 231:261-273.
4. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003, 63(12):3154-3161.
5. Yum L.Y., Robyn L.W. Anti-ErbB2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 2002, 50:569-587.
6. Brandt-Rauf P.W., Pincus M.R., Carney W.P. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncogenesis 1994, 5:313-329.
7. Meric F., Hung M., Hortobagyi G.N., Hunt K. HER2/neu in the management of invasive breast cancer. JAm Coll Surg 2002, 194(4):488-501.
8. Koeppen H.K., Wright B.D., Burt A.D., Quirke P., McNicol A.M., Dybdal N.O., et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001, 38:96-104.
9. Kita Y., Tseng J., Horan T., Wen J., Philo J., Chang D., et al. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem Biophys Res Commun 1996, 226:59-69.
10. Baxevanis C.N., Sotiropoulou P.A., Sotiriadou N.N., Papamichail M. Cancer immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 2004, 53:166-175.
11. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment ofHER2-overexpressing metastatic breast cancer. JClin Oncol 2002, 20(3):719-726.
12. Nielsen U.B., Marks J.D. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharma Sci Technol Today 2000, 3(8):282-291.
13. Nielsen U.B., Kirpotin D.B., Pickering E.M., Drummond D.C., Marks J.D. Anovel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol 2006, 7(24):1-15.
14. Belimezi M.M., Merkouri D.P., Baxevanis C.N., Mamalaki A. Growth inhibition ofbreast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Cancer Immunol Immunother 2006, 55:1091-1099.
15. De Lorenzo C., Palmer D.B., Piccoli R., Ritter M.A., D'Alessio G. Anew human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 2002, 8:1710-1719.
16. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9:67-81.
17. Jothy S., Yuan S.Y., Shirota K. Transcription of carcinoembryonic antigen in normal colon and colon carcinoma. Am J Pathol 1993, 143:250-257.
18. Kim J., Kaye F.J., Henslee J.G., Shively J.E., Park J.G., Lai S.L., et al. Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer 1992, 52:718-725.
19. Cournoyer D., Beauchemin N., Boucher D., Benchimol S., Fuks A., Stanners C.P. Transcription of genes of the carcinoembryonic antigen family in malignant and nonmalignant human tissues. Cancer Res 1988, 48:3153-3157.
20. Chester K.A., Mayer A., Bhatia J., Robson L., Spencer D. Recombinant anti-carcinoembryonic antigen antibodies. Cancer Chemother Pharmacol 2000, 46:S8-S12.
21. Hong H., Sun J., Cai W. Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomarker Insights 2008, 3:435-451.
22. Khazaeli M.D., Conry B.M., LoBugllo A. Human response to monoclonal antibodies. JImmunother 1994, 15:42-52.
23. Hoogenboom H.R., Marks J.D., Griffiths A.D., Winter G. Building antibodies from their genes. Immunol Rev 1992, 130:41-68.
24. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994, 13:3245-3260.
25. Clark M.A., Hawkins N.J., Papaioannou A., Fiddes R.J., Ward R.L. Isolation of human anti-c-erbB-2 Fabs from a lymph node-derived phage display library. Clin Exp Immunol 1997, 109(1):166-174.
26. Rothe A., Klimka A., Tur M.K., Pfitzner T., Huhn M., Sasse S., et al. Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines. Int J Mol Med 2004, 14(4):729-735.
27. Krauss J. Recombinant antibodies for the diagnosis and treatment of cancer. Mol Biotechnol 2003, 25:1-17.
28. Disis M.L., Bernhard H., Gralow J.R., Hand S.L., Emery S.R., Calenoff E., et al. Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp 1994, 187:198-211.
29. Pupa S.M., Menard S., Andreola S., Colnaghi M.I. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993, 53(24):5864-5866.
30. Haidopoulos M., Konstadoulakis M.M., Antonakis P.T., Alexiou G.D. Circulating anti-CEA antibodies in the sera of patients with breast cancer. Euro J Surg Onc 2000, 26(8):742-746.
31. Hoogenboom H.R., Griffiths A.D., Johnson K.S., Chiswell D.J., Hudson P., Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991, 19(15):4133-4137.
32. Arbabi M., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 1997, 414:521-526.
33. Harlow E.D., Lane D. Using antibody: a laboratory manual 1999, 105-150. Cold Spring Press, New York.
34. Margolis M.L., Hyzy J.B., Schenken L.L., Schepart B.S. Serum tumor markers in non-small cell long cancer, a comparative analysis. Cancer 1994, 73:605-609.
35. Barbas C.F., Burton D.R. Phage display, a laboratory manual 2001, 9.23-9.52. Cold Sprin Harbor Laboratory Press, New York. J.K. Scot, G.J. Silverman (Eds.).
36. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of proteins of immunological interest 2001, US Department of Health and Human Services. 5th ed.
37. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., et al. Differential responses of human tumor cell lines to antip185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37:255-263.
38. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCa€erty J., Winter G. By-passing immunization human antibodies from V-gene libraries displayed on phage. JMol Biol 1991, 222:581-597.
39. Wong C., Waibel R., Sheets M., Mach J.P., Finmern R. Human scFv antibody fragments specific for the epithelial tumour marker Muc-1, selected by phage display on living cells. Cancer Immunol Immunother 2001, 50:93-101.
40. Breitling F., Duebel S., Seehaus T., Klewinghaus I., Little M. Asurface expression vector for antibody screening. Gene 1991, 104:147.
41. Watters J.M., Telleman P., Junghans R.P. An optimized method for cell-based phage display panning. Immunotechnology 1997, 3:21-29.
42. Gao C., Mao S., Ronca F., Zhuang S., Quaranta V., Wirsching P., et al. De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods. JImmunol Methods 2003, 274:185-197.
43. Robin S., Petrov K., Dintinger T., Kujumdzieva A., Tellier C., Dion M. Comparison of three microbial hosts for the expression of an active catalytic scFv. Mol Immunol 2003, 39(12):729-738.
44. Goodell V., Waisman J., Salazar L.G., Rosa C., Link J., Coveler A.L., et al. Level of HER-2/neu protein expression in breast cancer may affect the development ofendogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008, 7(3):449-454.
45. Disis M.L., Knutson K.L., Schiffman K., Rinn K., McNeel D.G. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000, 62:245-252.
46. Visco V., Bei R., Moriconi E., Gianni W., Muraro R. ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Amer J Patho 2000, 156(4):1417-1424.
47. Nagorsen D., Keilholz U., Rivoltini L., Schmittel A., Letsch A., Asemissen A.M., et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000, 60:4850-4854.
48. Cai X., Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci U S A 1995, 92(14):6537-6541.
49. Bruin R., Spelt K., Mol J., Koes R., Quattrocchio F. Selection of high-affinity phage antibodies from phage display libraries. Nat Biotechnol 1999, 17(4):397-399.
50. Yip Y.L., Hawkins N.J., Clark M.A., Ward R.L. Evaluation of different lymphoid tissue sources for the construction of human immunoglobulin gene libraries. Immunotechnology 1997, 3(3):195-203.
51. Chothia C., Lesk A.M., Gherardi E., Tomlinson I.M., Walter G., Marks J.D., et al. Structural repertoire of the human VH segments. JMol Biol 1992, 227(3):799-817.
52. Desmetz C., Maudelonde T., Mangé A., Solassol J. Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev Proteomics 2009, 6(4):377-386.
53. Heitner T., Moor A., Garrison J.L., Marks C., Hasan T., Marks J.D. Selection of cell binding and internalizing epidermal growth factor antibodies from a phage display library. JImmunol Methods 2001, 248:17-30.
54. Hoogenboom H.R. Overview of antibody phage-display technology and its applications. Methods Mol Biol 2002, 178:1-37.
55. Liu B., Conrad F., Cooperberg M., Kirpotin D., Marks J. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res 2004, 64:704-710.
56. Poul M.A., Becerril B., Nielsen U.B., Morisson P., Marks J.D. Selection of tumor-specific internalizing human antibodies from phage libraries. JMol Biol 2000, 301:1149.
57. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993, 90(14):6444-6448.
58. Becerril B., Poul M., Marks J.D. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun 1999, 255:386-393.
59. Hudson P.J., Kortt A.A. High avidity scFv multimers; diabodies and triabodies. JImmunol Methods 1999, 231:177-189.
60. Huang B., Foote L.J., Lankford T.K., Davern S.M., McKeown C.K., Kenne S.J. Adiabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting. Biochem Biophysical Res Commun 2005, 327:999-1005.
61. Neve R.M., Nielsen U.B., Kirpotin D.B., Poul M., Marks J.D., Benz C.C. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophysical Res Commun 2001, 280:274-279.
62. Ghetie M.A., Podar E.M., Ilgen A., Gordon B.E., Uhr J.W., Vitetta E.S. Homo dimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A 1997, 94:7509.
63. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19:6102-6114.
64. Frankel A.E. New HER2-directed therapies for breast cancer. Clin Cancer Res 2002, 8:1720-1730.
65. Tai W., Mahato R., Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. JControl Release 2010, 1-12.
66. Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004, 15:5268-5282.
67. De Lorenzo C., Cozzolino R., Carpentieri A., Pucci P., Laccetti P., D'Alessio G. Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 2005, 26(11):1890-1895.
68. Wagner C., Clark B.R., Rickard K.J., Shively J.E. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: determining of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay. JImmunol 1983, 130:2302-2307.